Supplementary Figure I: Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma

Published: 04-01-2021| Version 3 | DOI: 10.17632/8wx2hd5twc.3
Contributor:
Kelsey Hirotsu

Description

Hirotsu KE, Rana J, Wang JY, Raghavan SS, Rieger KE, Srinivas S, Fan AC, Kwong BY, Novoa RA, Zaba LC, Clinicopathologic characterization of enfortumab-vedotin associated cutaneous toxicity in patients with urothelial carcinoma, Journal of the American Academy of Dermatology (2021) doi: https://doi.org/10.1016/j.jaad.2020.11.067.

Files